In one analysis, individuals with obesity treated with GLP‐1s incurred significantly higher annual healthcare costs than individuals with obesity without GLP‐1 use (~$7000 higher in the first year, and $4200 higher in the second year) [6, 82]. The gene discussed is GCG; the disease is Obesity.